Ocuphire Pharma doses first patient in phase 3 VEGA-3 clinical trial - Ophthalmology Times
Ocuphire Pharma has initiated the VEGA-3 phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia treatment, aiming for a non-invasive, convenient alternative. The trial follows positive results from the VEGA-2 study, which demonstrated rapid onset, favorable safety profile, and sustained effect. VEGA-3 will evaluate 545 participants with presbyopia, with top-line data expected in 2025, potentially supporting a supplemental New Drug Application.
Related Clinical Trials
Reference News
Ocuphire Pharma has initiated the VEGA-3 phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia treatment, aiming for a non-invasive, convenient alternative. The trial follows positive results from the VEGA-2 study, which demonstrated rapid onset, favorable safety profile, and sustained effect. VEGA-3 will evaluate 545 participants with presbyopia, with top-line data expected in 2025, potentially supporting a supplemental New Drug Application.
Ocuphire Pharma has dosed the first patient in its VEGA-3 phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia treatment, aiming for a non-invasive alternative. The VEGA-3 trial is randomized, double-masked, placebo-controlled, and multi-center, evaluating the solution in 545 participants. Top-line data is expected in 2025.
Ocuphire Pharma's VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% in presbyopia has dosed its first participants, with top-line data expected in H1 2025. The LYNX-2 Phase 3 trial for visual acuity issues post-keratorefractive surgery is ongoing, with top-line data anticipated in Q1 2025.
Ocuphire Pharma initiates VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia, with top-line data expected in H1 2025. The company also anticipates LYNX-2 Phase 3 trial data for visual acuity issues post-keratorefractive surgery in Q1 2025.
Ocuphire Pharma has initiated the VEGA-3 phase 3 trial, evaluating phentolamine ophthalmic solution 0.75% for presbyopia in 545 participants. The trial aims to assess efficacy and safety as a noninvasive alternative to traditional measures, with topline data expected in 2025.